Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: Predictive factors for response and long-term outcome

Journal of Clinical Oncology

Volumn 18, Issue 16, 2000, Pages 3031-3037

  Lokhorst, H M ^a   Schattenberg, A ^a   Cornelissen, J J ^a   van Oers, M H J ^a   Fibbe, W ^a   Russell, I ^a   Donk, N W C J v d ^a   Verdonck, L F ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; METHOTREXATE;

ADULT; ARTICLE; BONE MARROW APLASIA; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LONG TERM CARE; LYMPHOCYTE TRANSFUSION; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; STEM CELL TRANSPLANTATION;

EID: 0033844816     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.16.3031     Document Type: Article

References (47)

1. Graft-versus-leukemia effect of donor lymphocyte transfusion in marrow grafted patients
2. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia
3. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation
4. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation
5. Graft-versus-host-disease as adoptive immunotherapy in patients with advanced hematological neoplasms
6. Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation
7. Graft-versus-myeloma effect: Proof of principle
8. Graft-versus-myeloma effect in two cases
9. Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): Evidence for a graft-versus-myeloma effect
10. Graft-versus-myeloma after donor leukocyte infusion: Maintenance of marrow remission but extramedullary relapse with plasmacytomas
11. Toxicity and efficacy of defined doses of CD4+ donor lymphocytes for treatment of relapse after allogeneic bone marrow transplantation
12. Donor lymphocyte transfusions and low-dose interleukin-2 in 2 patients with relapsed CML after syngeneic BMT
13. Cytotoxic T-lymphocyte (CTL) responses against acute or chronic myeloid leukemia
14. The human immunodominant minor histocompatibility antigen HA-1 represents a diallelic gene with a single amino acid polymorphism
15. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease
16. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation
17. Cellular kinetics in multiple myeloma: A new approach to staging and treatment
18. Effective treatment of advanced multiple myeloma refractory to alkylating agents
19. Intermediate-dose melphalan (IDM) combined with G-CSF (filgastrim) is an effective and safe induction therapy for autologous stem cell transplantation in multiple myeloma
20. Detection of minimal residual disease in multiple myeloma and acute leukemia
21. Bone marrow transplantation
22. Chronic graft-versus-host syndrome in man: A long-term clinico-pathologic study in 20 Seattle patients
23. Complete donor T cell chimerism is accomplished in patients transplanted with bone marrow grafts containing a fixed low number of T cells
24. HLA class II restricted T-cell reactivity to a developmentally regulated antigen shared by leukemic cells and CD34+ early progenitor cells
25. Cellularly defined minor histocompatibility antigens are differentially expressed on human hematopoietic progenitor cells
26. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: Impact of infused and residual donor T cells
27. Characterization of T cell repertoire in patients with graft-versus leukemia following donor lymphocyte infusion
28. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes
29. Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen specific cytotoxic T lymphocytes
30. Allogeneic cell therapy with donor peripheral blood stem cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation
31. Donor leukocyte infusions inducing remissions repeatedly in a patient with recurrent multiple myeloma after allogeneic bone marrow transplantation
32. Adjuvant alpha-interferon improves complete remission rates following allogeneic transplantation for multiple myeloma
33. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia
34. Thymidine kinase (TK) gene-transduced human lymphocytes can be highly purified, remain fully functional, and are killed efficiently with ganciclovir
35. CD8-depleted lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation
36. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: A retrospective case-matched study from the European Group for Blood and Marrow Transplantation
37. Allogeneic marrow transplantation for multiple myeloma: An analysis of risk factors on outcome
38. Molecular eradication of multiple myeloma is possible after allogeneic and autologous transplantation of hematopoietic cells
39. Molecular and clinical remissions in multiple myeloma: Role of autologous and allogeneic transplantation of hematopoietic cells
40. Double high-dose chemoradiotherapy with autologous stem cell transplantation can induce molecular remissions in multiple myeloma
41. Collection, tumor contamination, and engraftment kinetics of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma
42. T-cell depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse
43. Successful T cell depleted allogeneic bone marrow transplantation in a child versus recurrent multiple extramedullary plasmacytomas
44. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host-disease
45. Optimizing the dose and timing of lymphocyte add-back in T-cell depleted BMT between HLA-identical siblings
46. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy
47. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases